Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Operating Income of -$62.28 million for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$62.28M | -176.3% |
| 2024 | $81.67M | +1649.9% |
| 2023 | -$5.27M | -111.4% |
| 2022 | $46.12M | -46.4% |
| 2021 | $86.03M | -50.5% |
| 2020 | $173.70M | +16.9% |
| 2019 | $148.57M | +2.9% |
| 2018 | $144.44M | +45.1% |
| 2017 | $99.54M | +83.6% |
| 2016 | $54.22M | +160.1% |
| 2015 | $20.84M | +494.9% |
| 2014 | -$5.28M | +91.5% |
| 2013 | -$61.92M | -46.8% |
| 2012 | -$42.17M | -11.7% |
| 2011 | -$37.75M | +5.9% |
| 2010 | -$40.12M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$60.23M | -247.5% | -596.1% |
| June 30, 2025 | $12.14M | -46.2% | +218.4% |
| March 31, 2025 | -$10.26M | -225.3% | -125.1% |
| September 30, 2024 | $40.84M | +401.9% | +81.0% |
| June 30, 2024 | $22.57M | +228.3% | +815.8% |
| March 31, 2024 | -$3.15M | -160.9% | -138.7% |
| September 30, 2023 | $8.14M | +634.3% | +146.3% |
| June 30, 2023 | -$17.59M | -255.0% | -439.8% |
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -176.3% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s operating income has declined by 55.2% (from -$40.12 million to -$62.28 million).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: